– Interos is an Arlington, VA-based supply chain risk management and operational resilience technology company.
– The company raised $100m in Series C funding.
– The round was led by NightDragon with participation from current investors Kleiner Perkins and Venrock.
– The new investment will be used to expand operations and business reach.

– Element Biosciences from San Diego develops DNA sequencing platform.
– The company closed a $276m Series C financing.
– Backers included new investors Janus Henderson Investors, Logos Capital, Meritech Capital Partners, Counterpoint Global (Morgan Stanley), and T. Rowe Price and existing investors Fidelity Management & Research Company, Foresite Capital, JS Capital Management LLC, RA Capital Advisors, and Venrock.
– The new investment will be used to scale commercial organization in anticipation of the launch of its next-generation sequencing solution.

– Altruist is a Los Angeles CA-based provider of platform for modern financial advisors.
– Company raised $50m in Series B funding.
– The round was led by Insight Partners, with follow-on participation from Series A investor Venrock, as well as Vanguard.
– The company intends to use the funds to expand operations and its product offerings.

– Waybridge, the supply chain platform for raw materials, announced it raised $30m in Series B funding co-led by Rucker Park Capital and Craft Ventures, with participation from Venrock.
– Waybridge solves fundamental inefficiencies in the supply chain, enabling clients to buy and sell commodities with less friction, have real-time visibility into their inventory, track shipments, and save time and money by turning many offline manual processes into automated digital processes.
– The new funding brings the company’s total funds raised to $40M.
– “The power of Waybridge is that we combine the financial, the logistical, and the technological into a single transactional platform that provides valuable insight for everyone in the supply chain,” said Brian O’Kelley, co-founder and CEO of Waybridge.

– Amunix Pharmaceuticals from South San Francisco develops masked, protease-activated immune-oncology therapeutics to bring the promise of these potent therapies to patients with solid tumor cancers.
– Series B $117m round was led by Viking Global Investors with participation from a premier syndicate of funds, including new investors Bain Capital Life Sciences, BlackRock, Franklin Templeton, Janus Henderson Investors, ArrowMark Partners, Avidity Partners, certain funds managed by Clough Capital Partners, and CaaS Capital Management and existing investors Redmile Group, Venrock, Casdin Capital, Omega Funds, Frazier Healthcare Partners, Longitude Capital, and Polaris Partners.